USPTO Issues Guidance on “Applicant Admitted Prior Art” in IPRs

Aug 31, 2020

Reading Time : 3 min

According to the memorandum, Patent Trial and Appeal Board (PTAB) panels have been inconsistent in deciding whether § 311(b)—which allows requests for IPR “only on the basis of prior art consisting of patents or printed publications”—allows the use of AAPA. Panels have generally interpreted the statute in three ways: (1) AAPA is technically a “prior art patent” and thus can be relied on, alone or in a combination, as a basis for IPR; (2) AAPA is neither a prior art patent nor a printed publication and thus cannot be relied on, whether alone or in a combination, as a basis for IPR; or (3) AAPA is neither a prior art patent nor a printed publication and thus cannot be relied on alone as a basis for IPR, but it may be combined with other prior art to demonstrate obviousness.  The memorandum requires the PTAB to apply this third interpretation.

In coming to this conclusion, the Patent Office explained that § 311(b) plainly requires a “basis” that is either a “prior art patent” or a “printed publication.” And because neither the challenged patent nor statements therein are a “prior art patent,” AAPA cannot form the necessary “basis” under § 311(b). As a result, AAPA cannot be used for anticipation or single-reference obviousness grounds because such grounds would lack an appropriate “basis.”

The memorandum clarifies, however, that AAPA may be used in conjunction with prior art that does qualify as a “basis” under § 311(b). In particular, AAPA can be used to show “general knowledge” in the art, which can in turn be used in an obviousness challenge. For example, AAPA can demonstrate “motivation to combine” or can supply a “missing limitation” in an obviousness combination. Of course, as with other evidence of general knowledge, the patent owner is free to challenge whether AAPA indeed demonstrates what the petitioner alleges.

The Patent Office further explained that using AAPA to show “general knowledge” does not run afoul of § 311(b) because other prior art serves as a “basis” (or “starting point”) for the petition. Indeed, it has been “longstanding practice” in reexamination proceedings—which are governed by a “materially-identical” statute to § 311(b)—to allow AAPA as evidence of general knowledge. The memorandum further notes that other statutes, such as those allowing expert declarations in IPRs, similarly allow “evidence outside a prior art patent or printed publication.”

In a final note, the Patent Office addressed an apparent inconsistency between its guidance and 37 C.F.R. § 42.104(b)(4), which asks petitioners to “specify where each element of the claim is found in the prior art patents or printed publications relied upon.” The memorandum explained that this regulation “requires specific information from the parties to ensure orderly proceedings, but does not narrow the scope of IPR petitions further than § 311 itself does,” citing other C.F.R. regulations that the PTAB does not strictly enforce.

Practice Tip:

In addition to clearing up some uncertainty in IPRs, the Patent Office may have provided a useful tool for petitioners by expressly allowing AAPA to supply missing limitations and reasons to combine in obviousness challenges. If used in this way, petitioners should be sure to characterize AAPA as “general knowledge” and use it in conjunction with a prior art patent or printed publication.

By that same token, patentees should be on the lookout for petitions that fail to properly characterize alleged AAPA as “general knowledge” or that fail to assert AAPA in conjunction with other art. Patentees should also keep in mind that AAPA can be challenged as failing to show the “general knowledge” alleged by the petitioner. Finally, patentees should be cautious regarding what subject matter they acknowledge as prior art or “background.”


1 Memorandum from Andrei Iancu, Under Secretary and Director, U.S. Patent and Trademark Office, to Members of the Patent Trial and Appeal Board (Aug. 18, 2020) (on file with the U.S. Patent and Trademark Office).

Share This Insight

Previous Entries

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.